- In April 2024, Roche Diagnostics announced the launch of a next-generation immunohistochemistry (IHC) assay designed to improve the accuracy of thyroid cancer subtyping. The new assay, integrated with Roche’s advanced diagnostic platform, aids pathologists in identifying tumor origin and supports personalized treatment planning. This development highlights Roche’s commitment to advancing cancer diagnostics through precision and automation technologies tailored for clinical settings
- In March 2024, Veracyte, Inc., a leader in genomic diagnostics, expanded access to its Afirma Genomic Sequencing Classifier (GSC) by partnering with key laboratory networks across Europe and Asia. This move is aimed at enhancing the availability of high-accuracy molecular diagnostics for indeterminate thyroid nodules globally. The expansion reinforces Veracyte’s mission to reduce unnecessary surgeries and improve diagnostic clarity through genomic innovation
- In February 2024, Siemens Healthineers introduced an upgraded version of its ultrasound imaging system, specifically optimized for thyroid cancer detection. The system features enhanced Doppler sensitivity and real-time elastography, allowing for more accurate characterization of thyroid nodules. This advancement supports clinicians in non-invasively assessing malignancy risk and underlines Siemens’ focus on innovation in diagnostic imaging
- In January 2024, Thermo Fisher Scientific announced a strategic collaboration with leading cancer research institutes to develop novel liquid biopsy assays for early detection and monitoring of thyroid cancers. The initiative leverages Thermo Fisher’s expertise in next-generation sequencing and aims to provide minimally invasive alternatives for patient management, emphasizing the growing trend toward precision oncology and real-time monitoring
- In December 2023, BioReference Laboratories launched a comprehensive thyroid cancer diagnostic panel combining molecular markers, imaging analysis, and clinical decision support tools. Designed to improve diagnostic workflows in hospital and outpatient settings, this panel reflects the increasing demand for integrated, multi-modal diagnostic solutions in endocrine oncology
